Intervention Review

You have free access to this content

Topical capsaicin (high concentration) for chronic neuropathic pain in adults

  1. Sheena Derry1,*,
  2. Andrew S C Rice2,3,
  3. Peter Cole4,
  4. Toni Tan5,
  5. R Andrew Moore1

Editorial Group: Cochrane Pain, Palliative and Supportive Care Group

Published Online: 28 FEB 2013

Assessed as up-to-date: 10 DEC 2012

DOI: 10.1002/14651858.CD007393.pub3


How to Cite

Derry S, Rice ASC, Cole P, Tan T, Moore RA. Topical capsaicin (high concentration) for chronic neuropathic pain in adults. Cochrane Database of Systematic Reviews 2013, Issue 2. Art. No.: CD007393. DOI: 10.1002/14651858.CD007393.pub3.

Author Information

  1. 1

    University of Oxford, Pain Research and Nuffield Department of Clinical Neurosciences, Oxford, Oxfordshire, UK

  2. 2

    Imperial College London, Pain Research, Department of Surgery and Cancer, Faculty of Medicine, London, UK

  3. 3

    Chelsea and Westminster Hospital NHS Foundation Trust, Department of Pain Medicine, London, UK

  4. 4

    Churchill Hospital, Oxford University Hospitals NHS Trust, Oxford Pain Relief Unit, Oxford, UK

  5. 5

    National Institute for Health and Clinical Excellence, Centre for Clinical Practice, Manchester, UK

*Sheena Derry, Pain Research and Nuffield Department of Clinical Neurosciences, University of Oxford, Pain Research Unit, Churchill Hospital, Oxford, Oxfordshire, OX3 7LE, UK. sheena.derry@ndcn.ox.ac.uk.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 28 FEB 2013

SEARCH

[Figure 1]
Figure 1. Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.
[Figure 2]
Figure 2. Forest plot of comparison: 1 8% capsaicin versus control (single dose), outcome: 1.1 PGIC much or very much improved at 8 and 12 weeks.
[Figure 3]
Figure 3. Forest plot of comparison: 1 8% capsaicin versus control (single dose), outcome: 1.2 PHN - at least 50% pain intensity reduction over weeks 2 to 8.
[Figure 4]
Figure 4. Forest plot of comparison: 1 8% capsaicin versus control (single dose), outcome: 1.6 HIVN - at least 30% pain intensity reduction over weeks 2 to 12.
[Figure 5]
Figure 5. Skin adverse event rates with capsaicin and control. Yellow symbols are studies recording all events (Group 1). Pink symbols are studies specifying that events are not recorded on the first day after treatment (Group 2). The blue symbol did not specify the period over which events were recorded (Group 2). Size of symbol is proportional to the size of the study
[Figure 6]
Figure 6. Forest plot of comparison: 1 8% capsaicin versus control (single dose), outcome: 1.10 Serious adverse events.
[Analysis 1.1]
Analysis 1.1. Comparison 1 8% capsaicin versus control (single dose), Outcome 1 PGIC much or very much improved at 8 and 12 weeks.
[Analysis 1.2]
Analysis 1.2. Comparison 1 8% capsaicin versus control (single dose), Outcome 2 PHN - at least 50% pain intensity reduction over weeks 2 to 8.
[Analysis 1.3]
Analysis 1.3. Comparison 1 8% capsaicin versus control (single dose), Outcome 3 PHN - at least 50% pain intensity reduction over 2 to 12 weeks.
[Analysis 1.4]
Analysis 1.4. Comparison 1 8% capsaicin versus control (single dose), Outcome 4 PHN - at least 30% pain intensity reduction over weeks 2 to 8.
[Analysis 1.5]
Analysis 1.5. Comparison 1 8% capsaicin versus control (single dose), Outcome 5 PHN - at least 30% pain intensity reduction over weeks 2 to 12.
[Analysis 1.6]
Analysis 1.6. Comparison 1 8% capsaicin versus control (single dose), Outcome 6 HIVN - at least 30% pain intensity reduction over weeks 2 to 12.
[Analysis 1.7]
Analysis 1.7. Comparison 1 8% capsaicin versus control (single dose), Outcome 7 Local skin reactions - group 1.
[Analysis 1.8]
Analysis 1.8. Comparison 1 8% capsaicin versus control (single dose), Outcome 8 Local skin reactions - group 2.
[Analysis 1.9]
Analysis 1.9. Comparison 1 8% capsaicin versus control (single dose), Outcome 9 Patch tolerability.
[Analysis 1.10]
Analysis 1.10. Comparison 1 8% capsaicin versus control (single dose), Outcome 10 Serious adverse events.
[Analysis 1.11]
Analysis 1.11. Comparison 1 8% capsaicin versus control (single dose), Outcome 11 Withdrawals.